Abstract
Background Currently, there is no standard chemotherapy for advanced oesophageal cancer, especially for those with recurrent or metastatic one.
Objective To retrospectively investigate the efficacy and safety of combination of nedaplatin with docetaxel in the treatment of Chinese patients with advanced oesophageal cancer.
Methods Patients with advanced oesophageal cancer from two specialist hospitals in Guangzhou received intravenously 60 mg/m2 docetaxel for 1 h, followed by 80 mg/m2 nedaplatin for 2 h, on day 1 for every 28 days. Cycles continued until documented disease progression, unacceptable toxicity or patient’s refusal. Kaplan–Meier analysis was used to estimate survival time.
Results Between 2008 and 2013, 368 patients were enrolled into the study. A total of 26 patients achieved complete response and 170 patients achieved partial response. The median of progression-free survival and overall survival were 4.4 months and 8.8 months, respectively. The non-hematological toxicities were generally mild to moderate; severe hematological toxicities included neutropenia and anaemia, which observed in 85 (23.1%) patients and 112 (30.4%) patients; thrombocytopenia was mild (mostly Grade1); there were no febrile neutropenia and treatment-related death.
Conclusions The combination regimen of nedaplatin with docetaxel is effective and safe.
Keywords
References
Li X, Zhao LJ, Liu NB, Zhang WC, Pang QS, Wang P, et al. Feasibility and efficacy of concurrent chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: a respective study of 116 cases from a single institution. Asian Pac J Cancer Prev. 2015;16(4):1463–9.
Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB Jr, Ajani JA, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236(3):376–84; discussion 84–5.
Gong Y, Ren L, Zhou L, Zhu J, Huang M, Zhou X, et al. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer Chemother Pharmacol.2009;64(2):327–33.
Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev. 2003;29(6):525–32.
Cao W, Xu C, Lou G, Jiang J, Zhao S, Geng M, et al. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer. Jpn J Clin Oncol. 2009;39(9):582–7.
Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) trial (JCOG9407). Jpn J Clin Oncol. 2001;31(9):419–23.
Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22(3):172–6.
Shimada M, Itamochi H, Kigawa J. Nedaplatin: a cisplatin derivative in cancer chemotherapy. Cancer Manag Res. 2013;5:67–76.
Yamazaki K, Hironaka S, Boku N, Yasui H, Fukutomi A, Yoshino T, et al. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum. Int J Clin Oncol. 2008;13(2):150–5.
Xu RH, Shi YX, Guan ZZ, Jiang WQ, Huang H, Ma ZY, et al. Phase II clinical trial of home-produced nedaplatin in treating advanced esophageal carcinoma. Ai Zheng. 2006;25(12):1565–8.
Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955–9.
Kajiura S, Hosokawa A, Yoshita H, Ueda Y, Ueda A, Mihara H, et al. Phase I study of docetaxel plus nedaplatin in patients with metastatic or recurrent esophageal squamous cell carcinoma after cisplatin plus 5-fluorouracil treatment. Am J Clin Oncol. 2016;39(1):13–7.
Funaki H, Miura S, Morioka E, Kaida D, Ohnishi T, Ohno Y, et al. Evaluation of combination chemotherapy with docetaxel and nedaplatin in patients with advanced or recurrent esophageal cancer. Gan To Kagaku Ryoho. 2014;41(12):2384–6.
Matsumoto H, Hirabayashi Y, Kubota H, Murakami H, Higashida M, Haruma K, et al. A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma. Anticancer Res. 2012;32(5):1827–31.
Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, et al. Second-line combination chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol. 2009;4(8):1017–21.
Nakajima Y, Suzuki T, Haruki S, Ogiya K, Kawada K, Nishikage T, et al. A pilot trial of docetaxel and nedaplatin in cisplatinpretreated relapsed or refractory esophageal squamous cell cancer. Hepatogastroenterology. 2008;55(86–87):1631–5.
Kanai M, Matsumoto S, Nishimura T, Shimada Y, Watanabe G, Kitano T, et al. Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. Int J Clin Oncol. 2007;12(3):224–7.
Osaka Y, Takagi Y, Hoshino S, Tachibana S, Tsuchida A, Aoki T. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting. Dis Esophagus. 2006;19(6):473–6.
Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17(9):2915–21.
Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2–3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57(2):425–33.
Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi K, Nishimura H, Tanigawa N. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil:a retrospective study. Dis Esophagus. 2008;21(6):496–501.
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.